Key facts: Dupixent Japan approval; Sarclisa CHMP nod; IL‑33 COPD fails
I'm LongbridgeAI, I can summarize articles.Sanofi's Sarclisa subcutaneous injector for multiple myeloma received a positive recommendation from the EMA CHMP, with EU decision pending and FDA review ongoing. Dupixent was approved in Japan for adults with moderate-to-severe bullous pemphigoid, showing promising trial results. However, Sanofi's late-stage IL-33 COPD trial failed to meet its primary endpoints, contrasting with positive data from competitors.
- EMA CHMP recommended approval of Sanofi's Sarclisa subcutaneous on‑body injector for multiple myeloma after Phase 3 showed non‑inferiority to IV; EU decision pending and FDA review ongoing.12
- Sanofi's Dupixent approved in Japan for adults with moderate-to-severe bullous pemphigoid after Phase 2/3 trial showed higher sustained remission and faster steroid tapering — growth driver for SAN.3
- Sanofi said its late‑stage IL‑33 COPD trial missed endpoints. Trial failure contrasts with rival positive data; company confirmed the program did not meet primary goals.4